AI Drug Discovery for Pharma and Biotech

Drug discovery

8

drugs

With orphan designations

Overview

Hutchinson-Gilford Progeria Syndrome (HGPS) is an ultra-rare, autosomal dominant genetic disorder caused by a LMNA gene mutation, leading to accumulation of progerin, a toxic protein. This results in accelerated aging, growth failure, alopecia, lipodystrophy, and severe atherosclerosis. Cardiovascular complications (myocardial infarction, stroke) drive early mortality, with median survival of ~14.5 years [1][5][7][10]. Diagnosis is clinical and confirmed via genetic testing [6][16].

Population

Affects ~1 in 4 million births, with >200 identified cases globally [1][7][13]. No sex or ethnic predilection [2][7].

Burden

Universal mortality by early teens (untreated); debilitating morbidity includes growth failure, joint contractures, and recurrent strokes [1][4][14]. Families face psychosocial strain and high care demands due to multisystem involvement [16][18].

Therapies

  • Lonafarnib (farnesyltransferase inhibitor): FDA-approved, extends lifespan by ~2.5 years [8][9].

  • Combination therapies: Triple therapy (lonafarnib + pravastatin + zoledronate) improves cardiovascular outcomes [3][9].

  • Investigational approaches: CRISPR-based gene editing, rapamycin, vitamin D supplementation, and microbiome modulation [3][5][12].

Categories: rare bone diseases, rare developmental anomalies during embryogenesis, rare genetic diseases, rare skin diseases

Research Papers

630 drug discovery papers related to Hutchinson-Gilford progeria syndrome, with 6 first-in-class and 4 next-in-class early-stage therapies forecasted to outperform the average preclinical success rate. Recent publications:

630 drug discovery papers related to Hutchinson-Gilford progeria syndrome, with 6 first-in-class and 4 next-in-class early-stage therapies forecasted to outperform the average preclinical success rate. Recent publications:

2026-06-17 | A toxic STING-SAMHD1 axis drives replication stress in progeria and cancer cells.

STING is an innate immune adaptor, classically activated by cytosolic DNA via cGAS-cGAMP to induce interferon signaling. Recent studies reveal that STING participates in non-canonical signaling pathways and localizes to the nucleus, where its functions remain poorly understood. In Hutchinson-Gilford Progeria Syndrome (HGPS), a premature aging disease caused by expression of the lamin-A mutant protein 'progerin', STING accumulates in the nucleus and drives chronic inflammation. Here, we show that replication stress is a trigger of STING nuclear accumulation and chromatin binding. In addition, we uncover that STING binds to nascent DNA and promotes replication stress in progeria and tumor cells. Mechanistically, STING causes replication fork slowing and stalling by limiting dNTPs availability. Upon fork stalling, STING hinders replication fork protection/stability by facilitating MRE11-mediated nascent DNA degradation (NDD). Importantly, STING's contribution to dNTP depletion and NDD is mediated by SAMHD1. Depletion of SAMHD1 phenocopies STING abrogation in reducing replication stress in progeria cells, and rescues replication fork speed and stability in STING-expressing tumor cells. These findings define a pathological STING-SAMHD1 axis that drives replication stress and genome instability in both progeria cells and tumor cells with elevated STING activity, uncovering a feedforward loop between innate immune signaling and impaired DNA replication.

Open article ↗



2026-05-22 | Discovery of NARF-interacting proteins.

Patients with Hutchinson-Gilford Progeria Syndrome manifest molecular defects in the nuclear lamina with unique phenotypic presentation in accelerated aging. The data in sum together with other biochemical and cellular studies suggested a central and critical role for the nuclear lamina in cellular aging, a process related to but separate from organismal aging. We used proteomics for unbiased discovery of NARF-interacting proteins.

Open article ↗



2026-05-10 | NLRP3 inflammasome dysregulation by endocrine-disrupting chemicals and heavy metals: Developmental programming, sex differences, and inflammaging across the lifespan.

Environmental exposure to heavy metals and endocrine-disrupting chemicals (EDCs) activates the NLRP3 inflammasome, driving chronic inflammation that worsens or may underlie cardiovascular disease, neurodegeneration, and accelerated aging. This review examines the molecular mechanisms by which lead, cadmium, mercury, arsenic, bisphenol A, phthalates, and dioxins modulate NLRP3 signaling. Lead and cadmium activate NLRP3 through mitochondrial dysfunction and oxidative stress, whereas mercury and arsenic suppress inflammasome assembly by preventing apoptosis-associated speck-like protein containing a CARD (ASC) oligomerization. EDCs engage receptor-mediated pathways: aryl hydrocarbon receptor (AhR) activation directly represses NLRP3 transcription, yet bisphenol A and phthalates override this suppression through NF-κB activation. Developmental timing critically determines outcomes such as prenatal exposures epigenetically programing persistent NLRP3 dysregulation. Sex hormones have been shown to modulate distinct inflammatory landscapes: estrogen suppresses NLRP3 via ERβ-dependent mechanisms, while testosterone amplifies inflammasome-dependent pathology. The skin serves as a primary interface for environmental chemical exposure and cutaneous NLRP3 activation. NLRP3-deficient mice exhibit 34% increased lifespan, and pharmacological inhibition with MCC950 extends lifespan in progeria models. The CANTOS trial demonstrated that targeting inflammation through IL-1β neutralization confers cardiovascular benefits in high-risk humans. These findings position NLRP3 as a central integrator through which the chemical exposome accelerates inflammaging and identify inflammasome inhibition as a therapeutic strategy for environmental disease prevention.

Open article ↗



2026-06-17 | A toxic STING-SAMHD1 axis drives replication stress in progeria and cancer cells.

STING is an innate immune adaptor, classically activated by cytosolic DNA via cGAS-cGAMP to induce interferon signaling. Recent studies reveal that STING participates in non-canonical signaling pathways and localizes to the nucleus, where its functions remain poorly understood. In Hutchinson-Gilford Progeria Syndrome (HGPS), a premature aging disease caused by expression of the lamin-A mutant protein 'progerin', STING accumulates in the nucleus and drives chronic inflammation. Here, we show that replication stress is a trigger of STING nuclear accumulation and chromatin binding. In addition, we uncover that STING binds to nascent DNA and promotes replication stress in progeria and tumor cells. Mechanistically, STING causes replication fork slowing and stalling by limiting dNTPs availability. Upon fork stalling, STING hinders replication fork protection/stability by facilitating MRE11-mediated nascent DNA degradation (NDD). Importantly, STING's contribution to dNTP depletion and NDD is mediated by SAMHD1. Depletion of SAMHD1 phenocopies STING abrogation in reducing replication stress in progeria cells, and rescues replication fork speed and stability in STING-expressing tumor cells. These findings define a pathological STING-SAMHD1 axis that drives replication stress and genome instability in both progeria cells and tumor cells with elevated STING activity, uncovering a feedforward loop between innate immune signaling and impaired DNA replication.

Open article ↗



2026-05-22 | Discovery of NARF-interacting proteins.

Patients with Hutchinson-Gilford Progeria Syndrome manifest molecular defects in the nuclear lamina with unique phenotypic presentation in accelerated aging. The data in sum together with other biochemical and cellular studies suggested a central and critical role for the nuclear lamina in cellular aging, a process related to but separate from organismal aging. We used proteomics for unbiased discovery of NARF-interacting proteins.

Open article ↗



2026-05-10 | NLRP3 inflammasome dysregulation by endocrine-disrupting chemicals and heavy metals: Developmental programming, sex differences, and inflammaging across the lifespan.

Environmental exposure to heavy metals and endocrine-disrupting chemicals (EDCs) activates the NLRP3 inflammasome, driving chronic inflammation that worsens or may underlie cardiovascular disease, neurodegeneration, and accelerated aging. This review examines the molecular mechanisms by which lead, cadmium, mercury, arsenic, bisphenol A, phthalates, and dioxins modulate NLRP3 signaling. Lead and cadmium activate NLRP3 through mitochondrial dysfunction and oxidative stress, whereas mercury and arsenic suppress inflammasome assembly by preventing apoptosis-associated speck-like protein containing a CARD (ASC) oligomerization. EDCs engage receptor-mediated pathways: aryl hydrocarbon receptor (AhR) activation directly represses NLRP3 transcription, yet bisphenol A and phthalates override this suppression through NF-κB activation. Developmental timing critically determines outcomes such as prenatal exposures epigenetically programing persistent NLRP3 dysregulation. Sex hormones have been shown to modulate distinct inflammatory landscapes: estrogen suppresses NLRP3 via ERβ-dependent mechanisms, while testosterone amplifies inflammasome-dependent pathology. The skin serves as a primary interface for environmental chemical exposure and cutaneous NLRP3 activation. NLRP3-deficient mice exhibit 34% increased lifespan, and pharmacological inhibition with MCC950 extends lifespan in progeria models. The CANTOS trial demonstrated that targeting inflammation through IL-1β neutralization confers cardiovascular benefits in high-risk humans. These findings position NLRP3 as a central integrator through which the chemical exposome accelerates inflammaging and identify inflammasome inhibition as a therapeutic strategy for environmental disease prevention.

Open article ↗



Access all drug discovery articles and probability of success in trials forecasts:

Access all drug discovery articles and probability of success in trials forecasts:

Drug Discovery Landscape

8 orphan drug designations for Hutchinson-Gilford progeria syndrome, including 2 approved therapies.

8 orphan drug designations for Hutchinson-Gilford progeria syndrome, including 2 approved therapies.

Drug

Therapy type

Regulator

Orphan designation

Approval

Sponsor

an adenine base editor (ABE) therapy delivered using AAV9, for the correction of 1824 C>T mutation in the LMNA gene

gene editing enzymes

FDA

2026-03-18

The Progeria Research Foundation

salicylsalicylic acid

small molecules

FDA

2024-07-03

J & D Pharmaceuticals LLC

(7S)-8,8-dimethyl-7-{[(2E)-3-phenyl-2-propen-1-yl]oxy}-7,8-dihydro-2H,6H-pyrano[3,2-g]chromen-2-one

small molecules

EMA

2022-08-10

Global Medical Services Sp. z o.o.

peptide conjugated phosphorodiamidate morpholino oligomer

oligonucleotides

FDA

2020-09-08

Lonafarnib [Zokinvy]

small molecules

EMA

2018-12-14

2022-07-19

TMC Pharma (EU) Limited

progerinin

small molecules

FDA

2018-10-02

PRG S&T Co., Ltd.

lonafarnib [ZOKINVY]

small molecules

FDA

2011-04-18

2020-11-20

Sentynl Therapeutics, Inc.

Pravastatin / zoledronic acid

small molecules

EMA

2010-06-09

Prenyl BIO SAS

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.